Chief Medical Officer
Pulmocide Ltd
London, England, United Kingdom
Lance has been working in clinical drug development for over 25 years across a broad range of therapeutic areas, taking new medicines from early- to late-stage clinical trials and on to marketing approvals. His work in infectious disease has included itraconazole for the treatment of fever of unknown origin in neutropenic patients, posaconazole in cryptococcus meningitis, and more recently at Pulmocide, inhaled opelconazole for the treatment of pulmonary aspergillosis. Lance received his Bachelor of Medicine and Bachelor of Surgery (MB.ChB) degree from the University of Cape Town, South Africa and holds a Master’s in Science in Pharmaceutical Medicine.
Disclosure(s): Pulmocide Ltd.: Employee (Ongoing), Stocks/Bonds (Ongoing)
Saturday, October 14, 2023
8:00 AM – 8:12 AM US ET